Gabapentin is an Efficacy Treatment for Facial Flushing and Erythema of Erythematotelangiectatic Rosacea: A Randomized Clinical noninferiority Trial [0.03%]
加巴喷丁治疗面部潮红和毛细血管扩张性玫瑰糠疹的疗效：一项随机临床非劣效性试验
Jinyu Wei,Mei Wan,Qiquan Chen et al.
Jinyu Wei et al.
Dermatological and nephrological complications after polymethyl methacrylate (PMMA) injections: a series of 239 cases [0.03%]
聚甲基丙烯酸甲酯(PMMA)注射后的皮肤和肾脏并发症：239例系列研究
Mayra Ianhez,Arthur Fidelis de Sousa,Eliandre Costa Palermo et al.
Mayra Ianhez et al.
Visual Thinking Strategies in Dermatology Residency: An Artful Way of Seeing [0.03%]
视觉思维策略在皮肤科住院医师培训中的应用——一种艺术化的思维方式
Turkan Banu Karatas,Travis W Blalock
Turkan Banu Karatas
Risk of Candida and Overall Fungal Infections with IL-17 Inhibitors in the Treatment of Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis [0.03%]
抑制白细胞介素17治疗汗腺炎的抗 candida 和总体真菌感染风险：系统评价和 meta 分析
Miranda K Branyiczky,Ryan S Huang,Mohannad Abu-Hilal
Miranda K Branyiczky
Sanyam Mehta,Kailash Bhatia,Chaitanya Namdeo
Sanyam Mehta
A Single Center Retrospective Cohort Study of Hydroxychloroquine-Related Adverse Events in Adults with Lymphocytic Cicatricial Alopecia [0.03%]
羟氯喹治疗淋巴细胞性瘢痕性脱发成人患者的回顾性队列研究：单一中心报告
Katelyn J Rypka,Zachary Wendland,Hannah Schull et al.
Katelyn J Rypka et al.
Histologic Distinction and Potential Misidentification of Proliferating Pilar Tumors versus Squamous Cell Carcinoma [0.03%]
扩张性毛囊瘤与鳞状细胞癌的组织病理学区别及鉴别诊断困难点
William Chai,Michael Nemeh,David Silvers et al.
William Chai et al.
Association between pre-transplant actinic keratosis and skin cancer in kidney recipients: A retrospective cohort study [0.03%]
肾脏移植受者的移植前光照性角化病与皮肤癌的关联：一项回顾性队列研究
Zachary J K Neubauer,Shari R Lipner
Zachary J K Neubauer
Melanoma and worry [0.03%]
黑色素瘤与焦虑
Warren R Heymann
Warren R Heymann
Response to ritlecitinib with or without narrow-band UVB add-on therapy in patients with active nonsegmental vitiligo: results from a phase 2b extension study [0.03%]
利特昔替尼单药或联合窄波UVB治疗活跃期节段外白癜风：IIb期延展研究结果
Yuji Yamaguchi,Elena Peeva,Roni Adiri et al.
Yuji Yamaguchi et al.
Background: Ritlecitinib demonstrated efficacy in a phase 2b trial of nonsegmental vitiligo. Objective: To evaluate the efficacy and to...